
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Vanda Pharmaceuticals Inc (VNDA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VNDA (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $12.67
1 Year Target Price $12.67
1 | Strong Buy |
1 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.62% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 261.76M USD | Price to earnings Ratio - | 1Y Target Price 12.67 |
Price to earnings Ratio - | 1Y Target Price 12.67 | ||
Volume (30-day avg) 3 | Beta 0.72 | 52 Weeks Range 3.81 - 5.54 | Updated Date 08/15/2025 |
52 Weeks Range 3.81 - 5.54 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When Before Market | Estimate -0.2933 | Actual -0.46 |
Profitability
Profit Margin -32.9% | Operating Margin (TTM) -73.21% |
Management Effectiveness
Return on Assets (TTM) -9.88% | Return on Equity (TTM) -13.01% |
Valuation
Trailing PE - | Forward PE 30.3 | Enterprise Value -52147155 | Price to Sales(TTM) 1.29 |
Enterprise Value -52147155 | Price to Sales(TTM) 1.29 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA 12.91 | Shares Outstanding 59089100 | Shares Floating 49364241 |
Shares Outstanding 59089100 | Shares Floating 49364241 | ||
Percent Insiders 7.21 | Percent Institutions 78.74 |
Upturn AI SWOT
Vanda Pharmaceuticals Inc

Company Overview
History and Background
Vanda Pharmaceuticals Inc. was founded in 2002. It is a biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs.
Core Business Areas
- Hetlioz: Hetlioz (tasimelteon) is a selective melatonin receptor agonist indicated for Non-24-Hour Sleep-Wake Disorder in adults and Smith-Magenis Syndrome in children.
- Fanapt: Fanapt (iloperidone) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.
Leadership and Structure
Vanda's leadership team includes Mihael H. Polymeropoulos, M.D., as Chairman, President and CEO. The organizational structure follows a typical biopharmaceutical model with departments for research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Hetlioz: Hetlioz (tasimelteon) is indicated for Non-24-Hour Sleep-Wake Disorder (N24HSWD) and Smith-Magenis Syndrome. Market share data is not publicly available but the primary competitor in the N24HSWD space is off-label melatonin use. Revenue from Hetlioz accounted for a substantial portion of Vanda's total revenue.
- Fanapt: Fanapt (iloperidone) is an atypical antipsychotic for schizophrenia. Fanapt competes with numerous other antipsychotics, including those from major pharmaceutical companies (e.g., risperidone, quetiapine). Market share information is not publicly available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for sleep disorders and schizophrenia treatments is large and growing.
Positioning
Vanda is a specialty pharmaceutical company focusing on niche markets with unmet needs. Its competitive advantage lies in its focus on specific indications and its expertise in developing and commercializing therapies for these indications.
Total Addressable Market (TAM)
The total addressable market for sleep disorders and schizophrenia is significant, estimated to be in the billions of dollars. Vanda is positioned to capture a portion of this market through its targeted therapies.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio targeting unmet medical needs
- Established sales and marketing infrastructure
- Strong intellectual property protection for key products
Weaknesses
- Reliance on a limited number of products
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trials and regulatory approvals
Opportunities
- Expansion into new indications for existing products
- Acquisition or licensing of new therapies
- Geographic expansion into international markets
Threats
- Competition from generic or biosimilar products
- Unfavorable regulatory changes
- Product liability claims
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- TEVA
Competitive Landscape
Vanda competes with large pharmaceutical companies. Its competitive advantage lies in its focus on niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by sales of Hetlioz and Fanapt.
Future Projections: Future growth projections are based on analyst estimates which include sales forecasts for existing products and potential new product approvals.
Recent Initiatives: Recent initiatives include clinical trials for new indications and efforts to expand market access for existing products.
Summary
Vanda Pharmaceuticals is a biopharmaceutical company with a specialized product portfolio, focusing on niche markets. Its strengths include established products and intellectual property. However, it faces the challenge of reliance on a limited product line and competition from larger players. Vanda needs to focus on expanding its pipeline and maintaining strong regulatory relationships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vanda Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2006-04-12 | Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 368 | Website https://www.vandapharma.com |
Full time employees 368 | Website https://www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.